Question by Olga: How often do you see Neuroleptic Malignant Syndrome?
I’ve been working as a Psychiatric RN for a number of years now and I have never seen a single case of NMS.

How often do we still see NMS in current times?

Best answer:

Answer by rb43081
It is certainly believed that the risk/incidence of NMS (and all acute extrapyramidal syndromes) should be decreasing with the increased use of newer drugs. On the other hand, ALL drugs are being used more often, perhaps for longer periods of time and possibly, in patients of greater risk (older, for example).

Take a look at this:

Mov Disord. 2006 May;21(5):589-98.

Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
Tarsy D, Baldessarini RJ.

Department of Neurology, Harvard Medical School, and Beth Israel-Deaconess Medical Center, Boston, Massachusetts 02215, USA. [email protected]

Abstract
Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modern APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.

=====================

Rex, a physician, in the midwest

Give your answer to this question below!

Luxury Drug Treatment in Massachusetts | Call 800-839-1682 For Help – Luxury Drug Treatment in Massachusetts |-Call 800-839-1682 For Help How would you like to see your family member recover from his addiction? Isn’t it a nice …

Pam Bondi says amendment would make Florida one of the most lenient …

Filed under: drug treatment centers in massachusetts

Only two other states, California and Massachusetts, have laws that are that relaxed. … Michigan and Montana, for example, don't specify there have to be medical marijuana dispensaries, according to pro-legislation Marijuana Policy Project spokesman …
Read more on PolitiFact

Camden Planning Board to Vote on Fox Hill Rehab January 2

Filed under: drug treatment centers in massachusetts

The Camden Planning Board delayed voting on a proposal to allow a high-end drug and alcohol rehabilitation clinic to operate at Fox Hill Estate, which is located in a residential district on upper Bayview Street, until January 2. The decision to delay …
Read more on Freepress Online

Contact lenses can deliver glaucoma drugs for a month

Filed under: drug treatment centers in massachusetts

Scientists from Massachusetts have created a contact lens that will deliver controlled amounts of medicine directly into the eyes of glaucoma patients continuously for up to a month. The researchers, from Massachusetts Eye and Ear Infirmary, Harvard …
Read more on Medical News Today

Top Scientific Minds Gather for Breakthrough Prize Symposium

Filed under: drug treatment centers in massachusetts

This scientific foundation underlies the circuit-based treatment of Parkinson's disease by deep brain stimulation. … For discoveries leading to the development of controlled drug-release systems and new biomaterials. … But the party's real stars …
Read more on UCSF News Services